These robust surges underscore AbbVie’s ability for swift gains, indicating that upcoming catalysts could propel the stock to ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

Close to two years after AbbVie handed over $48 million for the rights to Ose Immunotherapeutics’ inflammation drug, the Big Pharma now wants the French biotech to keep an eye on the asset for a while ...

AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago pharma confirmed to Fierce Biotech. “We have terminated clinical activity around ...

AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer’s agreement to lower its drug prices for Medicaid and a White House decision ...

With $10 billion earmarked to grow its U.S. operations through 2035, AbbVie continues to lay out the particulars on its decade-long domestic investment strategy. The Chicago-area Big Pharma has kicked ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s second-quarter earnings report, JPMorgan reaffirmed its Overweight rating and ...

You can read Bitcoin candlestick charts with zero experience — here’s how to understand patterns, spot trends, and start making smarter crypto moves. Bitcoin candlesticks are a popular tool among ...